Organogenesis Holdings (ORGO) Capital Expenditures (2018 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Capital Expenditures of $3.1 million for Q1 2026, down 13.24% year-over-year from $3.6 million in Q1 2025, and down 32.37% quarter-over-quarter from $4.7 million in Q4 2025.
Organogenesis Holdings (ORGO) Capital Expenditures (2018 - 2026) Analysis & Trends
Organogenesis Holdings' Capital Expenditures history runs 9 years deep, the most recent figure standing at $3.1 million for Q1 2026.
- In Q1 2026, Capital Expenditures fell 13.24% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $13.7 million (up 6.21% YoY), while the FY2025 annual figure was $14.2 million, up 41.06% from the prior year.
- Capital Expenditures for Q1 2026 stood at $3.1 million, down from $4.7 million in the prior quarter.
- The five-year high for Capital Expenditures was $19.2 million in Q3 2023, with the low at -$104000.0 in Q2 2023.
- The 5-year median for Capital Expenditures is $3.3 million (2023), against an average of $5.0 million.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures tumbled 100.95% in 2023, then surged 3288.46% in 2024.
- Organogenesis Holdings' Capital Expenditures stood at $10.7 million in 2022, then sank by 68.81% to $3.3 million in 2023, then advanced by 1.11% to $3.4 million in 2024, then surged by 38.41% to $4.7 million in 2025, then slumped by 32.37% to $3.1 million in 2026.
- Business Quant data shows ORGO's Capital Expenditures at $3.1 million in Q1 2026, $4.7 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Organogenesis Holdings | 229.04 Mn | 182.20 Mn | 20.08 Mn | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Mn |
| Jun 30, 2026 | 1.10 Mn |
| Mar 31, 2026 | 3.15 Mn |
| Mar 31, 2026 | 3.15 Mn |
| Dec 31, 2025 | 4.65 Mn |
| Dec 31, 2025 | 4.65 Mn |
| Sep 30, 2025 | 2.24 Mn |
| Sep 30, 2025 | 2.24 Mn |
| Jun 30, 2025 | 3.64 Mn |
| Jun 30, 2025 | 3.64 Mn |
| Mar 31, 2025 | 3.63 Mn |
| Mar 31, 2025 | 3.63 Mn |
| Dec 31, 2024 | 3.36 Mn |
| Dec 31, 2024 | 3.36 Mn |
| Sep 30, 2024 | 2.57 Mn |
| Sep 30, 2024 | 2.57 Mn |
| Jun 30, 2024 | 3.32 Mn |
| Jun 30, 2024 | 3.32 Mn |
| Mar 31, 2024 | 786,000.00 |
| Mar 31, 2024 | 786,000.00 |